A Study of GDC-0449 (Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer

This study is ongoing, but not recruiting participants.

Study NCT00636610 Information provided by Genentech

First Received: March 5, 2008 Last Updated: September 8, 2009 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Additional conditions recognized in this trial

Colorectal Neoplasms

More general conditions related to this trial

Interventions listed in this trial

bevacizumab
chemotherapy
GDC-0449
placebo

More general drug interventions related to this trial

Sponsors listed in this trial

Genentech